Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Boehringer Ingelheim
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Fondazione per la Medicina Personalizzata
Hoffmann-La Roche
Western Regional Medical Center
Hoffmann-La Roche
Fondazione del Piemonte per l'Oncologia
Fondazione del Piemonte per l'Oncologia
Hoffmann-La Roche